Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

Also called NCT04029480

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04029480
  • EU CT 2022-501085-21-00
  • WHO UTN U1111-1279-3984
  • EudraCT 2017-003455-35
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Malaysia, Mauritius, Mexico, Philippines, Poland, Russia, Saudi Arabia, Türkiye, Ukraine, United Arab Emirates, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04029480. Randomized; double masking; primary purpose treatment. Start 2019-10-08 (actual); primary completion 2025-04-11 (actual). Results posted on 2025-10-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ertugliflozin 5 mg
Intervention (Drug)
Ertugliflozin 15 mg
Intervention (Drug)
Placebo to ertugliflozin 15 mg
Intervention (Drug)
Placebo to ertugliflozin 5 mg
Intervention (Biological)
Insulin
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct04029480
Content hash
7128cdcc4f2930d0ee2b086957162ec4abff3b3decd109a5f5b997132af6748d